Find the Right Market Report

Search thousands of industry reports, market insights, and research studies in one place.

Not sure where to start? Try one of these:
Explore healthcare market intelligence and industry insights
Towards Healthcare

Japan Cell Therapy Top Companies and Strategic Involvements

Date : 01 June 2026

Top Companies in the Japan Cell Therapy Market & Their Offerings

Japan Cell Therapy Market Companies are Astellas Pharma, Takara Bio, JCR Pharmaceuticals, REPROCELL, Terumo Corporation, Fujifilm Cellular Dynamics, Sumitomo Pharma, CMIC Group, Gilead Sciences, Novartis, Bristol Myers Squibb, BlueRock Therapeutics

Vendor Key Offerings in the Japan Cell Therapy Market
Astellas Pharma Developing regenerative ophthalmology therapies and advanced iPSC-based cell therapy platforms through its AIRM initiatives.
Takara Bio Provides cell processing instruments, gene engineering technologies, viral vectors, and research reagents supporting regenerative medicine and CAR-T development.
JCR Pharmaceuticals Focuses on regenerative medicine and cell therapy manufacturing, including advanced biologics and stem cell-related therapies.
REPROCELL Offers StemRNA technology, GMP-grade iPSC services, stem cell banking, and regenerative medicine solutions.
Terumo Corporation Supplies automated cell processing systems and closed manufacturing platforms widely used in Japanese hospitals and cell therapy centers.
Fujifilm Cellular Dynamics Develops iPSC-derived therapies for cardiology, neurology, and regenerative medicine applications.
Sumitomo Pharma Advancing iPSC-derived therapies for Parkinson’s disease and regenerative medicine products, including neural progenitor cell therapies.
CMIC Group Provides end-to-end cell and gene therapy support services, including regulatory consulting, clinical studies, and commercialization support.
Gilead Sciences Markets CAR-T therapies such as Yescarta in Japan through its Kite Cell Therapy division, focused on hematologic oncology.
Novartis Offers CAR-T therapies, including Kymriah for blood cancer treatment in Japan’s expanding cell therapy market.
Bristol Myers Squibb Provides CAR-T therapies such as Breyanzi and Abecma for hematological malignancies.
BlueRock Therapeutics Develops iPSC-derived therapies targeting Parkinson’s disease, ophthalmology, and cardiovascular disorders.

What are the Recent Developments in the Japan Cell Therapy Market? 

  • In December 2025, BioCardia Inc. completed early discussions with Japan’s PMDA to advance its CardiAMP Cell Therapy for heart failure with reduced ejection fraction (HFrEF) into formal regulatory consultation. This marks an important step toward potential approval in Japan and reflects growing progress in bringing advanced cell-based cardiac therapies closer to clinical use.
  • In May 2025, FUJIFILM Toyama Chemical submitted a regulatory application in Japan for FF-31501, an autologous synovial mesenchymal stem cell therapy designed to treat meniscus injuries. This filing represents a key milestone, bringing the treatment closer to potential approval and future clinical use in regenerative medicine.

Supply Chain Analysis

R&D

  • Japan is a global leader in cell therapy research and development, with a strong focus on induced pluripotent stem (iPS) cells and advanced regenerative treatments. The country is actively developing and commercializing therapies for conditions such as Parkinson’s disease and severe heart failure. This progress is supported by a fast-track regulatory system that speeds up approval of regenerative medicines.
  • Key players: Astellas Pharma, Takeda, and Sumitomo Pharma

Regulatory Approvals

  •  Japan follows a dual regulatory framework for cell therapy governed by the Pharmaceuticals and Medical Devices Agency (PMDA), under the PMD Act and the Act on the Safety of Regenerative Medicine (ASRM). This system enables a conditional, time-limited approval pathway that allows earlier patient access while confirming long-term safety and effectiveness.
  • Key players: Astellas Pharma, Takeda, and Daiichi Sankyo

Patient Support and Services 

  • Japan is a global hub for regenerative medicine, offering strictly regulated, MHLW-approved stem cell therapies with strong clinical safety standards. Patient services often include controlled cell processing, advanced personalized treatment planning, and support such as medical coordination and international patient assistance.
  • Key players: Astellas Pharma, Takeda, and Fujifilm Cellular Dynamics

Market Growth

The Japan cell therapy market size was estimated at USD 250 million in 2025 and is predicted to increase from USD 308.08 million in 2026 to approximately USD 2018.85 million by 2035, expanding at a CAGR of 23.23% from 2026 to 2035.

Japan Cell Therapy Market Size is USD 308.08 Million in 2026.

Ready to make better
healthcare business decisions?

Speak with a healthcare analyst about your research, consulting, or platform needs.

Talk to an Analyst Contact Sales